Moderna to expand commercial network across six additional countries in Europe

By Jane Byrne contact

- Last updated on GMT

© GettyImages/Jonathan Kitchen
© GettyImages/Jonathan Kitchen

Related tags: Moderna, mRNA therapeutics, Lonza

The US biotech says it will establish a commercial presence in Belgium, Denmark, Norway, the Netherlands, Poland, and Sweden to support the delivery of mRNA vaccines and therapeutics locally.

The company only recently announced plans for four new subsidiaries in Malaysia, Taiwan, Singapore, and Hong Kong.

Moderna currently has commercial subsidiaries in Italy, France, Germany, Spain, Switzerland, and the UK.  

It also has several key manufacturing partnerships across Europe with CDMOs including Lonza in Switzerland and the Netherlands, ROVI in Spain, and Recipharm in France.

Strategic goals

Moderna’s pipeline currently includes 40 development programs, of which 25 are in clinical trials.  

The pharma group is looking to scale up the manufacturing and distribution of its COVID-19 vaccine while advancing other mRNA vaccine candidates and therapeutics to prevent and treat diseases with significant unmet needs across infectious diseases, immuno-oncology, rare and ultra-rare diseases, and autoimmune diseases.

Its goals include the plan to develop a pan-respiratory annual booster vaccine, with the idea of continuously customizing it. Moderna reckons such a broad annual single booster vaccine covering multiple viruses, such as COVID-19, influenza, and Respiratory Syncytial Virus could create value for the healthcare system through compliance, convenience for the customer, and a reduction in vaccine administration cost.

The company also intends to develop first-in-class vaccines against latent viruses for which there are no approved vaccines today. It has clinical candidates in development, in that respect, including Epstein-Barr Virus (P1), human immunodeficiency virus (P1), and Cytomegalovirus (P3).

“Latent viruses infect the body, lay dormant, and do not replicate but possess the capacity to activate, causing disease. In addition, new emerging evidence highlights that latent viral infections may have yet unknown negative effects.”

Related news

Show more

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Related suppliers

Follow us

Products

View more

Webinars